We read with great interest the article by Akutagawa et al. in this journal in which the authors describe that PI3K inhibitors unexpectedly profoundly inhibited myeloproliferation in an myelodysplastic/myeloproliferative neoplasm mouse model driven by hyperactive RAS, suggesting a new therapeutic strategy in juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML).The basis for all RAS pathway-oriented treatment concepts is the identification of RAS pathway hyperactivation in patients.Due to the fact that in CMML more than one mol. aberration can be detected in the majority of patients, functional tests may be important to better estimate the contribution of a particular mol. aberration in the pathogenesis of the malignancy.In JMML, in which mol. aberrations are mainly restricted to the RASopathy genes, including NRAS, KRAS, NF1, CBL and PTPN11, the spontaneous formation of colony-forming unit-granulocyte-macrophage (CFU-GM) due to granulocyte/macrophage colony-stimulating factor (GM-CSF)-specific hypersensitivity is a hallmark feature of disease, which has been included in the diagnostic criteria.We have originally reported that extensive in vitro formation of CFU-GM without exogenous growth factors can also be found in a subset of patients with CMML.We demonstrated that this spontaneous myeloid colony formation in CMML is a GM-CSF-dependent in vitro phenomenon and could also show that CMML patients with high spontaneous CFU-GM growth (>100/105 PBMNC) have a worse prognosis compared with patients with low CFU-GM growth, suggesting a clin. significance of our observation.We speculated that spontaneous myeloid colony formation might be a surrogate parameter of RAS pathway hyperactivation in CMML.To test this hypothesis, we performed next-generation sequencing (NGS) from stored peripheral blood mononuclear cells (PB MNC) obtained from 100 CMML patients, in whom in vitro cultures have been performed during the last years.In vitro culture data were then correlated with mol. aberrations of RAS pathway components.The diagnosis of CMML was made according to the diagnostic criteria of the World Health Organization classification of 2008.For mol. characterization, we used NGS with amplicon-based target enrichment of 39 CMML-associated genes, including ASXL1, EGFR, KRAS, SF3A1, ATRX, ETV6, MET, SF3B1, BCOR, EZH2, NF1, SRSF2, BRAF, FLT3, NPM1, STAG2, CBL, GNAS, NRAS, TET2, CDKN2A, IDH1, PRPF40B, TP53, CEBPA, IDH2, PTPN11, U2AF1, CSF1R, JAK2, RUNX1, WT1, CSF3R, KDM6A, SETBP1, ZRSR2, DNMT3A, KIT and SF1.Assuming that clones that are too small are unlikely to significantly impact hematopoiesis, only mutations with an allele burden of 20% or higher were considered as pos. for anal.CFU-GM growth in the absence of exogenous cytokines was assessed using semisolid cultures as previously described.In 40 CMML patients, mutations in at least one of the RASopathy genes were detected; in 60 patients, no mutations in RAS pathway components or such mutations with allele frequencies <20% were found.In the 40 patients with RAS pathway mutations, we found mol. aberrations of the NRAS gene in 19, KRAS in 6, NF1 in 3, CBL in 10 and PTPN11 in 2 patients, resp.Mutations of RAS pathway components were mutually exclusive, only low levels of more than one RASopathy mutations were found in some patients.In all patients with RAS pathway mutations, addnl. mutations were observed in other genes, particularly in components of DNA methylation and/or the spliceosome as previously reported by others.Results of semisolid cultures show that in CMML patients in whom mol. aberration in RAS pathway components could be detected had a much higher spontaneous myeloid colony formation than CMML patients without RAS pathway mutations.The median number of spontaneously formed CFU-GM/105 MNC was 147.5 (range 0-1009) in RAS-pos. patients as compared with 2 (0-812) in RAS-neg. patients (P<0.00001 by the Wilcoxon's rank-sum test).Unstimulated myeloid colony formation in RAS-pos. CMML patients is also much higher than the spontaneous formation of CFU-GM in normal individuals (median 4.8/105 PBMNC, range 3.5-8.5), which has been reported by us previously.The incidence of RAS pathway mutations was 72% (21/29) in CMML patients with high-colony growth (>100/105 PBMNC) and 27% (19/71) in patients with low spontaneous CFU-GM formation (P<0.0001 by the chi square test).In eight patients, high CFU-GM growth was observed without evidence of genetic aberrations in RAS signaling.This may indicate that addnl. mol. aberrations of the RAS pathway, which are not covered by our targeted NGS panel, may cause spontaneous cell proliferation, or, alternatively, that other signaling pathways may also play a certain role in this in vitro phenomenon.Our findings suggest that high spontaneous myeloid colony growth in CMML is significantly associated with mol. aberrations of genes involved in RAS signaling and thus seems to reflect RAS pathway hyperactivation in patients with CMML.Therefore, spontaneous colony formation in semisolid cultures could be a helpful functional test to identify patients who are potential candidates for treatment concepts designed for patients with RAS pathway-driven hematol. malignancies.
